Share

Merus has dosed the first patient in a Phase I clinical trial of MCLA-158 to treat patients with solid tumours with an initial focus on metastatic colorectal cancer.

The first-in-human trial follows approval of an investigational new drug (IND) application by the US Food and Drug Administration (FDA) for MCLA-158 last month.

This approval has lead the way for Merus to conduct the trial in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Initially, the open-label, multi-centre trial will be carried out across various sites in Europe.

The trial includes two parts, a dose escalation and a dose expansion phase.

The dose escalation part aims to determine the appropriate dose of MCLA-158, while the dose expansion aspect will examine safety and tolerability of the defined dose of MCLA-158 for solid tumours patients.

“We believe MCLA-158 has the potential to address features that limit currently approved colorectal cancer-targeted therapies.”

Both parts will also evaluate the preliminary anti-tumour activity of single-agent MCLA-158.

Merus CEO Ton Logtenberg said: “The commencement of our Phase I clinical trial of MCLA-158 is an important milestone for the advancement of our pipeline of bispecific antibodies obtained from our Biclonics technology platform.

“We believe MCLA-158 has the potential to address features that limit currently approved colorectal cancer-targeted therapies, including issues with off-target toxicity and inability to target tumour stem cells, and thus, potentially treat a broader population of patients more effectively.”

MCLA-158 has been developed to bind to cancer stem cells demonstrating leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) and epidermal growth factor receptors (EGFR).

Functional review of patient-derived colorectal tumours previously showed that MCLA-158 was more effective at inhibiting tumour growth and promoting apoptosis than cetuximab, an approved targeted therapy comparator for metastatic colorectal cancer.